Saturday 17 October 2026
Export MSLE’s income statement to Excel — free account
Satellos Bioscience Inc.
MSLE Healthcare Biotechnology
In the quarter to June 2026, EPS fell 42.5% and free cash flow fell 65.7%, each against the same quarter a year earlier.
6.46
0.38
−5.56%
Follow MSLE
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 2.64 | 4.80 | 5.04 | 7.68 | 3.84 | 0.05 | 0.25 | 1.81 | 3.56 | 4.52 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | 16.08 | 12.72 | 48.96 | 27.36 | 16.08 | 30.48 | 12.00 | 7.08 | 11.22 | 7.92 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | — | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | — | — | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | (1) | (1) | (1) | (1) | (1) | (12) | (9) | (12) | (21) | (25) | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | (1) | (1) | (1) | (1) | (1) | (12) | (9) | (12) | (21) | (25) | |||||
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 3 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | (3.20) | (2.40) | (3.70) | (2.86) | (1.73) | (6.12) | (3.00) | (1.68) | (2.16) | (1.70) | |||||
| Cash flow | (2.86) | (2.68) | (2.40) | (3.31) | (1.06) | (2.00) | (1.48) | (1.49) | (1.91) | (1.62) | |||||
| Capex | (0.01) | 0.00 | (0.01) | (0.01) | 0.00 | 0.69 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | (2.87) | (2.68) | (2.41) | (3.32) | (1.06) | (1.31) | (1.48) | (1.49) | (1.91) | (1.62) | |||||
| Book value | 4.97 | 2.38 | (1.36) | 0.98 | (0.87) | 4.17 | 0.87 | 4.19 | 4.93 | 1.90 | |||||
| Shares, m | 0 | 0 | 0 | 1 | 1 | 2 | 3 | 7 | 10 | 15 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (1) | (1) | (1) | (2) | (1) | (4) | (4) | (11) | (18) | (24) | ||||
| Capex | 0 | — | 0 | 0 | — | 1 | 0 | 0 | 0 | 0 | |||||
| Free cash flow | (1) | (1) | (1) | (2) | (1) | (3) | (4) | (11) | (18) | (24) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 2 | 1 | 0 | 0 | (1) | 3 | 0 | 27 | 47 | 28 | ||||
| Total debt | — | — | — | — | — | — | — | — | — | — | |||||
| Net debt | (2) | (1) | 0 | (1) | 0 | (4) | (1) | (29) | (49) | (28) | |||||
| Shareholders’ equity | 2 | 1 | 0 | 0 | (1) | 8 | 3 | 30 | 47 | 28 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (48.32) | (65.54) | (217.65) | (235.05) | (146.71) | (236.78) | (117.61) | (62.64) | (49.39) | (60.20) | ||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (64.98) | (367.58) | (955.67) | 0.00 | (22,347.13) | |||||
| ROE | (50.35) | (73.81) | (722.59) | (14,680.40) | 3,572.03 | (317.08) | (159.00) | (71.94) | (53.39) | (66.37) | |||||
Negative figures in brackets.
Latest quarter Jun 2021
Charts ten years each
Satellos Bioscience Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NBP NovaBridge Biosciences | $149.6M | — (loss-making) | — (loss-making) | −88.54% (below 0%: shrinking) | n/m | +34.25% (above 0%: growing) | 100.00% | 0.00% | Compare |
| CNTN Canton Strategic Holdings, Inc. | $149.0M | 9.0× | — | — | n/m | −600.39% (below 0%: shrinking) | 100.00% | (80.37%) | Compare |
| CDXS Codexis, Inc. | $148.9M | — (loss-making) | — (loss-making) | −2.69% (below 0%: shrinking) | n/m | +48.60% (above 0%: growing) | 76.45% | (75.29%) | Compare |
| MENS Jyong Biotech Ltd. | $147.0M | — | — | — | — | — | — | — | Compare |
| MSLE Satellos Bioscience Inc. | $145.1M | — (loss-making) | — | — | n/m | −65.66% (below 0%: shrinking) | 99.26% | 0.00% | |
| MOLN Molecular Partners AG Sponsored ADR | $143.5M | — (loss-making) | — (loss-making) | −98.86% (below 0%: shrinking) | n/m | +23.77% (above 0%: growing) | 0.00% | 0.00% | Compare |
| TARA Protara Therapeutics, Inc. | $141.8M | — (loss-making) | — | — | n/m | −28.10% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ALXO ALX Oncology Holdings Inc. | $138.3M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | +31.65% (above 0%: growing) | 0.00% | 0.00% | Compare |
| NKTX Nkarta, Inc. | $138.2M | — (loss-making) | — | — | n/m | −29.19% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $145.2M | — | — | −93.70% | — | +23.77% | 0.00% | 0.00% |
Satellos Bioscience Inc. (MSLE) key facts
- Satellos Bioscience Inc. (MSLE) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, MSLE traded at $6.46, a market capitalization of $145.1 million.
- Return on equity was −66.4% and debt-to-equity 0.00.
Satellos Bioscience Inc. (MSLE) Latest News
No news at this impact. Lower the threshold for more.